Table 3.
Person‐y | All Second Invasive Eventsa | ER+ or PR+ | ER– and PR– | |||||
---|---|---|---|---|---|---|---|---|
Cases, No. | HRb (95% CI) | Cases, No. | HRb (95% CI) | Cases, No. | HRb (95% CI) | |||
IBC in ipsilateral breast away from original DCIS and in contralateral breast | White | 971,003 | 4741 | 1.00 | 3776 | 1.00 | 630 | 1.00 |
Black | 126,291 | 755 | 1.34 (1.24‐1.45) | 547 | 1.24 (1.13‐1.36) | 149 | 1.93 (1.60‐2.40) | |
Asian | 125,104 | 648 | 1.06 (0.97‐1.17) | 497 | 0.99 (0.89‐1.10) | 107 | 1.45 (1.15‐1.82) | |
Hispanic | 98,900 | 489 | 1.05 (0.95‐1.16) | 388 | 1.05 (0.94‐1.17) | 71 | 1.14 (0.88‐1.47) | |
P heterogeneity < .0001 | ||||||||
IBC in same quadrant of same breast as original DCIS | White | 709,275 | 431 | 1.00 | 327 | 1.00 | 62 | 1.00 |
Black | 89,081 | 83 | 1.51 (1.18‐1.93) | 63 | 1.47 (1.10‐1.95) | 11 | 1.48 (0.75‐2.90) | |
Asian | 86,294 | 71 | 1.15 (0.87‐1.52) | 55 | 1.16 (0.84‐1.59) | 13 | 1.49 (0.75‐2.98) | |
Hispanic | 72,785 | 60 | 1.16 (0.88‐1.54) | 47 | 1.22 (0.89‐1.67) | 12 | 1.63 (0.85‐3.13) | |
P heterogeneity = .80 |
Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HR, hazard ratio; IBC, invasive breast cancer; PR, progesterone receptor; SEER, Surveillance, Epidemiology, and End Results.
Second IBCs included those positive for ER or PR (ER+ or PR+), those negative for both ER and PR (ER–PR–), and those with no information on ER and PR.
Hazard ratios were adjusted for the following: age (20‐39, 40‐49, 50‐59, 60‐69, or ≥70 years) and year of the primary DCIS diagnosis (1990‐1999, 2000‐2009, or 2010‐2015); registry; treatment for primary DCIS (no surgical treatment, breast‐conserving surgery alone, breast‐conserving surgery followed by radiation therapy, mastectomy, or unknown); and histopathological features of primary DCIS, including the tumor size (<2 cm, 2‐5 cm, ≥5 cm, or unknown), grade (well differentiated, moderately differentiated, poorly differentiated, or unknown), histology (comedo, papillary, cribriform, solid, or not otherwise specified), and hormone receptor expression (positive, negative, or unknown).